Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director | June 11, 2026 | June 15, 2026 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Director · President and CEO | February 03, 2024 | February 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,500 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 38,500 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F2: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
F2: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
OCULAR THERAPEUTIX, INC
Report date February 03, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 608,343 |
Reported balance
After 2024-02-03 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-03 · Grant · Acquired 180,400 · Balance 608,343 F1: On February 3, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. |
| Common StockSEC Table I · non-derivative | Direct | 588,701 |
Reported balance
After 2024-02-05 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-05 · Sale · Acquired 19,642 · Balance 588,701 F2: Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2024. The sales do not represent a discretionary trade by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.94, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.18 · Expires 2034-02-02 | Direct | 549,400 |
Reported balance
After 2024-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-03 · Grant · Acquired 549,400 · Balance 549,400 F4: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 6,500 |
Reported balance
Holding disclosure · report date 2024-02-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,500 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 3, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2: Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2024. The sales do not represent a discretionary trade by the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.94, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001193125-26-271165 · ownership.xml · derivative · entry 2 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271165 · ownership.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,500 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:10 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0000950170-25-087889 · ownership.xml · derivative · entry 2 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2035-06-17 F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:10 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087889 · ownership.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0000950170-24-076715 · ownership.xml · derivative · entry 2 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2034-06-20 F2 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076715 · ownership.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 23:26 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 19,642 | $4.86 | $95,460.12 |
DisclosureSEC source: 0001104659-24-011195 · tm245295-1_4seq1.xml · nonDerivative · entry 2 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,701 F2 · shares: Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2024. The sales do not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.94, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| February 03, 2024 Filed Feb 6, 2024 23:26 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 549,400 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001104659-24-011195 · tm245295-1_4seq1.xml · derivative · entry 4 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 549,400 Underlying: Common Stock · 549,400 shares Expires 2034-02-02 F4 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| February 03, 2024 Filed Feb 6, 2024 23:26 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 180,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-011195 · tm245295-1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 608,343 F1 · shares: On February 3, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:00 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 18,338 | $4.95 | $90,773.10 |
DisclosureSEC source: 0001104659-24-010231 · tm245049-1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,943 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 30, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · kind: The reporting person's sale of shares of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 6,500 shares, with the reporting person's indirect purchase of 6,500 shares of common stock at a price of $3.81 per share effected August 30, 2023. The reporting person has paid to the Corporation an aggregate amount of $7,401.55, representing the amount of the profit realized in connection with the short-swing transaction. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 30, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · shares: The reporting person's sale of shares of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 6,500 shares, with the reporting person's indirect purchase of 6,500 shares of common stock at a price of $3.81 per share effected August 30, 2023. The reporting person has paid to the Corporation an aggregate amount of $7,401.55, representing the amount of the profit realized in connection with the short-swing transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.82 to $5.06, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) this Form 4. Read SEC document |
| August 30, 2023 Filed Sep 5, 2023 12:27 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 6,500 | $3.81 | $24,765.00 |
DisclosureSEC source: 0001104659-23-098019 · tm2325262d1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 6,500 Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:57 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015209 · doc4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 06, 2023 Filed Feb 9, 2023 00:29 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 19,669 | $4.24 | $83,396.56 |
DisclosureSEC source: 0001104659-23-014678 · tm235900-1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,281 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2023. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.32, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 00:32 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 536,900 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001104659-23-009410 · tm235116-1_4seq1.xml · derivative · entry 2 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,900 Underlying: Common Stock · 536,900 shares Expires 2033-01-29 F3 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| January 30, 2023 Filed Feb 2, 2023 00:32 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 176,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009410 · tm235116-1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,950 F1 · shares: On January 30, 2023, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. F2 · balance_after: Includes 363,050 shares of common stock of the Company underlying unvested RSUs. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:06 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023125 · doc4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 00:28 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 560,200 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001104659-22-012918 · tm225652-1_4seq1.xml · derivative · entry 2 Mattessich Antony C. · CIK 0001709900 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,200 Underlying: Common Stock · 560,200 shares Expires 2032-02-02 F3 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 00:28 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 186,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-012918 · tm225652-1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,650 F1 · shares: On February 3, 2022, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service to the Company, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. F2 · balance_after: Includes 186,750 shares of common stock of the Company underlying unvested RSUs. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 23:27 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042087 · doc4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-10-27 F1 · derivative.exercise_date: The shares underlying this option vest as follows: These shares will vest in full on October 28, 2022. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 12:49 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 5,000 | $9.89 | $49,450.00 |
DisclosureSEC source: 0001104659-21-108777 · tm2125747-1_4seq1.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.88 to $9.89, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 455,000 | $0.00 Strike: $18.31 | $0.00 |
DisclosureSEC source: 0001104659-21-025785 · tm217246-3_4seq1.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 23:28 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001104659-20-009945 · a4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-01-29 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:53 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 40,000 | $2.81 | $112,400.00 |
DisclosureSEC source: 0001104659-19-034632 · a4.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.79 to $2.82, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 23:26 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-19-000889 · a4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 20:30 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 20,000 | $5.95 | $119,000.00 |
DisclosureSEC source: 0001104659-18-053039 · a4.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.93 to $5.97, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 20:43 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 16,900 | $6.23 | $105,287.00 |
DisclosureSEC source: 0001104659-18-051518 · a4.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,900 Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 21:34 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $5.47 | $0.00 |
DisclosureSEC source: 0001104659-18-006258 · a4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2028-01-30 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 22:15 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | PurchaseCommon Stock | 21,000 | $4.29 | $90,090.00 |
DisclosureSEC source: 0001104659-17-073177 · a4.xml · nonDerivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director · President and C.E.O. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:44 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 590,000 | $0.00 Strike: $10.94 | $0.00 |
DisclosureSEC source: 0001104659-17-040955 · a4.xml · derivative · entry 1 Mattessich Antony C. · CIK 0001709900 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,000 Underlying: Common Stock · 590,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: Vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and 2.0833% of the shares vesting monthly thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.